Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)
An Open Label, Single Center, Adaptive Phase I Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist)
The present study aims to evaluate the impact of 5 days oral administration of ronacaleret 100 miligram (mg) and 400 mg on changes in circulating CD34+ cells, when ronacaleret is followed by the administration of a single dose of plerixafor in healthy human volunteers.
This single centre adaptive design study will be carried out in 2 parts. The part A will evaluate the change in peripheral circulating CD34+ cells in response to two different 5 day regimens of ronacaleret (100 mg or 400 mg once daily), given in conjunction with a single dose of plerixafor (0.24 mg/kilogram [kg]) sub-cutaneously (SC) on the evening of the final days dosing approximately 12 hours before collection of CD34+ cells on day 6. Subjects (5 each) will be assigned to either one of the ronacaleret arms, in an open fashion. Comparisons will be made in the change from baseline to end of treatment peripheral CD34+ cell counts. Part A will be conducted in two cohorts with 5 subjects being enrolled into each of the 2 treatment arms making up the first cohort. Cohort 2 will involve up to 5 further subjects being enrolled into each treatment arm.
The structure of part B will be finalized following a review of data generated in part A.
The total study duration of Part A for each subject including the screening, treatment and follow-up periods will be approximately 7 weeks.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Kansas
-
Overland Park、Kansas、アメリカ、66211
- GSK Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- A male or female between 18 and 65 years of age (inclusive).
- Healthy as determined by a physician, based on a medical evaluation and with an estimated Glomerular Filtration Rate (GFR) of >=60 mL/min /1.73 m^2 using the four variable Modification of Diet in Renal Disease (MDRD) equation.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5 x upper limit of normal (ULN) (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Female of non-child bearing potential, or female subjects and male subjects with female partners of child-bearing potential willing to use protocol-specified methods of contraception to prevent pregnancy during the study.
- Body weight of 55 kg or more and body mass index (BMI) of 20.0 to 35.0 kg/m^2 (inclusive).
- Capable of giving written informed consent.
Exclusion Criteria:
- A positive pre-study drug/alcohol screen.
- A positive test for HIV, B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- History of or therapy for osteoporosis
- Subject has had treatment for any condition relating to the thyroid/parathyroid gland which in the opinion of the investigator may influence the subjects production of PTH
- Subjects with any contraindications or know allergies to receiving plerixafor
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones).
- Subjects taking calcium and/or vitamin D supplements, during or within 2 weeks of study initiation
- Subjects taking any concomitant medications
- Specific laboratory abnormalities at screening like Serum calcium (total or albumin-adjusted) outside the central laboratory reference range, PTH outside the normal range, Creatine phosphokinase (CPK) outside the normal range
- Subjects with abnormal Vitamin D (Vitamin D, 25-Hydroxy) levels may be enroled if repeat lab results, obtained within 14 days of initial screening assessments, are within the normal range
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females.
- Lactating or pregnant females as determined by positive serum human chorionic gonadotropin (hCG) test at screening or prior to dosing.
- The subject has participated in a clinical trial within 30 days or 5 half-lives of the IP prior to the first dosing day in the current study.
- Unable to refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Ronacaleret 100 mg
Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
|
Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
|
実験的:Ronacaleret 400 mg
Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
|
Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Mean change from baseline in CD34+ cell counts
時間枠:Baseline and upto Day 14
|
The mean fold change from baseline in the number of circulating CD34+ cells for all treatment arms will be assessed.
Samples will be collected at screening, Day 4 and Day 5 (2 hrs post ronacaleret dose), Day 6 (12 hrs and 14 and 16 hrs post plerixafor dose) and Day 14
|
Baseline and upto Day 14
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Spontaneous AE reporting
時間枠:Up to 14 days
|
Adverse events (AEs) will be collected from the start of Investigation Product (IP) and until the follow-up visit
|
Up to 14 days
|
Clinical laboratory safety data
時間枠:Up to 14 days
|
Clinical laboratory tests will include hematology, clinical chemistry and urinalysis
|
Up to 14 days
|
Measure of vital signs to access safety and tolerability
時間枠:Up to 14 days
|
Vital sign measurements will include systolic and diastolic blood pressure and pulse rate.
Subjects should have been in a supine or semi-supine (recumbent) position for at least 5 minutes prior to taking measurements
|
Up to 14 days
|
PTH responses
時間枠:Up to 6 days
|
Parathyroid hormone (PTH) has been shown to stimulate osteoblasts and osteoclasts and also associated with increased numbers of circulating CD34+ve cells
|
Up to 6 days
|
Quantification of the number of stem cells
時間枠:Part B will be detailed in an amendment to the protocol following a data review of part A
|
The number of stem cells from the various hematopoietic lineages through colony forming unit assays in Part B of the study
|
Part B will be detailed in an amendment to the protocol following a data review of part A
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 116610
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
移植、幹細胞の臨床試験
-
Rutgers, The State University of New Jersey完了
-
Sun Yat-sen Universityまだ募集していません子宮頸癌 | 化学療法効果 | ネオアジュバント療法 | Programmed Cell Death 1 Receptor / アンタゴニストと阻害剤
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
-
National Cancer Institute (NCI)積極的、募集していない低分化型甲状腺がん | 難治性分化型甲状腺がん | 難治性甲状腺癌 | 濾胞性バリアント甲状腺乳頭がん | Tall Cell Variant 甲状腺乳頭がん | 分化型甲状腺がん | 甲状腺濾胞癌 | 甲状腺乳頭癌 | 甲状腺腫瘍細胞癌アメリカ
-
National Cancer Institute (NCI)Exelixis完了再発甲状腺がん | 低分化型甲状腺がん | ステージ I 甲状腺乳頭癌 | II期の甲状腺乳頭癌 | III期の甲状腺乳頭がん | Tall Cell Variant 甲状腺乳頭がん | ステージ I 甲状腺濾胞癌 | II期甲状腺濾胞がん | III期の甲状腺濾胞がん | ステージ IVA 甲状腺濾胞癌 | ステージ IVA 甲状腺乳頭癌 | ステージ IVB 甲状腺濾胞癌 | ステージ IVB 甲状腺乳頭癌 | IVC 期の甲状腺濾胞がん | IVC 期の甲状腺乳頭がん | 甲状腺腫瘍性濾胞癌アメリカ
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)完了低分化型甲状腺がん | 再発性分化型甲状腺がん | 円柱状細胞バリアント甲状腺乳頭癌 | 濾胞性バリアント甲状腺乳頭がん | 転移性甲状腺濾胞癌 | 転移性甲状腺乳頭癌 | 再発甲状腺濾胞癌 | 再発甲状腺乳頭癌 | ステージ III 分化型甲状腺がん AJCC v7 | ステージ III 甲状腺濾胞癌 AJCC v7 | ステージ III 甲状腺乳頭がん AJCC v7 | ステージ IV 甲状腺濾胞癌 AJCC v7 | ステージ IV 甲状腺乳頭癌 AJCC v7 | ステージ IVA 分化型甲状腺がん AJCC v7 | ステージ IVA 甲状腺濾胞癌 AJCC v7 | ステージ IVA 甲状腺乳頭癌 AJCC v7 | ステージ IVB 分化型甲状腺がん... およびその他の条件アメリカ
Ronacaleret 100 mgの臨床試験
-
Hospices Civils de LyonGlaxoSmithKline募集
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.完了
-
Johnson & Johnson Pharmaceutical Research & Development...引きこもった
-
DSM Nutritional Products, Inc.完了
-
Kirby Institute募集
-
CymaBay Therapeutics, Inc.完了